GÜLGÜN YENİŞEHİRLİ, YUNUS BULUT, Ebru GÜNDAY

Yoğun bakım ünitesinde yatan hastaların kan kültürlerinden izole edilen Candida albicans suşlarında antifungallere duyarlılık

Yoğun bakım ünitesinde yatan hastaların kan kültürlerinden izole edilen 68 Candida albicans izolatının, amfoterisin B, flukonazol, itrakonazol ve flusitozin duyarlılıkları belirlenmiştir. Tüm izolatlar amfoterisin B, flukonazol ve flusitozine duyarlı bulunmuştur. İki C.albicans izolatının itrakonazole doza bağımlı duyarlı olduğu gözlenmiştir. Sonuç olarak hastanemiz yoğun bakımında yatan hastaların kan kültürlerinden izole edilen C.albicans suşlarında antifungal direnci bulunmamaktadır.

Anahtar Kelimeler:

Mikolojik tiplendirme teknikleri, Candida albicans, İlaç direnci, fungal, Kültür ortamı

Antifungal susceptibility of Candida albicans isolates recovered from blood cultures of intensive care unit patients

The in vitro activities of amphotericin B, fluconazole, itraconazole and flucytosine were determined against 68 Candida albicans isolates recovered from blood cultures of intensive care unit patients. All isolates were found to be susceptible to am-photericin B, fluconazole and flucytosine. Dose-dependent susceptibility to itraconazole was observed in only two C.albicans isolates. In conclusion, resistance is uncommon in C.albicans strains isolated from blood cultures of intensive care unit patients in our hospital.

Keywords:

Mycological Typing Techniques, Candida albicans, Drug Resistance, Fungal, Culture Media,

PDF

___

1. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S: The epidemiology of hematogenous candidiasis caused by different Candida species, Clin Infect Dis 1997;24(6):1122-8.
2. Aquino VR, Lunardi LW, Goldani LZ, Barth AL: Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil, Braz J Infect Dis 2005;9(5):411-8.
3. Arıkan S, Arslan Ş, Hasçelik G, Günalp A: Hacettepe Üniversitesi hastanesinde kan kültürlerinden izole edilen mayaların antifungal ajanlara in vitro duyarlılıkları, Mikrobiyol Bült 2001;35(3):433-41.
4. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M: Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland, J Clin Microbiol 2002;40(9):3489-92.
5. Bakir M, Cerikcioglu N, Barton R, Yagci A: Epidemiology of candidemia in a Turkish tertiary care hospital, APMIS 2006;114(9):601-10.
6. Basetti M, Righi E, Costa A et al: Epidemiological trends in nosocomial candidemia in intensive care, BMC Infect Dis 2006;6:21.
7. Colombo AL, Nucci M, Park BJ et al: Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers, J Clin Microbiol 2006;44(8):2816-23.
8. Colombo AL, Perfect J, DiNubile M et al: Global distribution and. outcomes for Candida species causing invasive candidiasis, results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis, Eur J Clin Microbiol Infect Dis 2003;22(8):470-4.
9. Cuenca-Estrella M, Rodriguez D, Almirante B et al: In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003, J Antimicrob Chemother 2005;55(2):194-9.
10. Hajjeh RA, Sof air AN, Harrison LH et al: Incidence of blood stream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population based active surveillance program, J Clin Microbiol 2004;42(4):1519-27.
11. Jarvis WR: Epidemiology of nosocomial fungal infections, with emphasis on Candida species, Clin Infect Dis 1995;20(6):1526-30.
12. Kauffman CA, Frame PT: Bone marrow toxicity associated with 5-fluorocytosine therapy, Antimicrob Agent Chemother 1977;ll(2):244-7.
13. Kibbler CC, Seaton S, Barnes RA et al: Management and outcome of bloodstream infections due to Candida species in England and Walles, J Hosp Infect 2003;54(l):18-24.
14. Leone M, Albanese J, Antonini F, Michel-Nguyen A, Blanc-Bimar MC, Martin C: Long-term epidemiological survey of Candida species: comparison of isolates found in intensive care unit and conventional wards, J Hosp Infect 2003;55(3):169-74.
15. Lu JJ, Lee SY, Chiueh TS: In vitro antifungal susceptibility testing of Candida blood isolates and evaluation of the E-test method, J Microbiol Immunol Infect 2004;37(6):335-42.
16. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard, 2nd ed. Document M27-A, National Committee for Clinical Laboratory Standards,Wayne, Pa (2002).
17. Ostrosky-Zeichner L, Rex JH, Pappas PG et al: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States, Antimicrob Agents Chemother 2003;47(10):3149-54.
18. Pfaller MA, Diekema DJ, Jones RN, Messer S A, Hollis RJ, the SENTRY Participants Group: Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicro bial Surveillance Program, 1997 to 2000, J Clin Microbiol 2002;40(3):852-6.
19. Pfaller MA, Jones RN, Messer S A, Edmond MB, Wenzel RP: National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program, Diagn Microbiol Infect Dis 1998;31(l):327-32.
20. Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ: In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candi da spp. Global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods, Antimicrob Agents Chemother 2002;46(ll):3518-21.
21. Rex JH, Pfaller MA, Walsh TJ et al: Antifungal susceptibility testing: practical aspects and current challenges, Clin Microbiol . Rev 2001;14(4):643-58.
22. Sheehan DJ, Hitchcock CA, Sibley CM: Current and emerging azole antifungal agents, Clin Microbiol Rev 1999;12(l):40-79.
23. Tortorano AM, Prigitano A, Biraghi E, Viviani MA, FIMUA-ECMM Candidaemia Study Group: The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isola tes and biofilm production, J Antimicrob Chemother 2005;56(4):777-9.
24. Verduyn Lunel FM, Meis JF, Voss A: Nosocomial fungal infections: candidemia, Diagn Microbiol Infect Dis 1999;34(3):213-20.
25. Vermes A, Guchelaar HJ, Dankert J: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions, J Antimicrob Chemother 2000;46(2): 171-9.
26. Voss A, Kluytmans JG, Koeleman L et al: Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals, Eur J Clin Microbiol Infect Dis 1996;15(12): 909-12.